Cutivate® (Fluticasone propionate) - A - Detailing from Skin Therapy Letter

 

Cutivate® (Fluticasone propionate)

 

 

  Content:

INTRODUCTION

 

 

  • A synthetic fluorinated corticosteroid recently introduced to Canada but has been available in the U.S market for a number of years
  • Fluticasone propionate is classified as a medium potency topical corticosteroid
  • Safety and efficacy has been established in a number of publications
  • Low systemic absorption of topical Cutivate and rapid metabolism and elimination of the drug is of advantage Evidence shows that intermittent use, twice weekly, of Cutivate can maintain eczema control. This is a significant advance.

There are limitations for regulators, pharmaceutical companies and pharmaceutical sales representatives to present clinical evidence following development of product monograph and drug approval. The product monograph is the starting point for this A-Detail™. It also contains evidence-based decision making processes, current standards of practice and clinical experience to provide a practical approach to the treatment of this condition.

Disclaimer: This A-Detail™ is meant to be a practical guide and does not necessarily reflect all risks, side-effects or situations associated with this product.


Next:   Clinical Experience